NCT00355901View on ClinicalTrials.gov

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

TerminatedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

November 30, 2012

Conditions
Ulcerative Colitis
Interventions
DRUG

Visilizumab (Nuvion®; HuM291)

Trial Locations (40)

2170

Liverpool

3000

Leuven

6160

Fremantle

8800

Roeselare

10021

New York

10029

New York

11030

Manhasset

11501

Mineola

17033

Hershey

29425

Charleston

30342

Atlanta

32610

Gainesville

40138

Bologna

40202

Louisville

44106

Cleveland

55905

Rochester

59037

Lille

61001

Kharkiv

63110

St Louis

75010

Paris

80054

Amiens

84107

Salt Lake City

94115

San Francisco

01655

Worcester

Unknown

Bedford Park

Box Hill

Brno

Prague

Dublin

Oslo

Tromsø

A-1090

Vienna

B-9000

Ghent

R3A-139

Winnipeg

L8N 3Z5

Hamilton

D-79106

Freiburg im Breisgau

H-7100

Béri Balogh Adám

H-2601

Vác

H-9024

Vásvari Pál

1105 AZ

Amsterdam

Sponsors
All Listed Sponsors
lead

PDL BioPharma, Inc.

INDUSTRY

NCT00355901 - An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis | Biotech Hunter | Biotech Hunter